Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

HIV Infections Clinical Trial

Official title:

Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00552240
• Other study ID #: 1100.1512
• Status: Completed
• Phase: Phase 4
• First received: September 28, 2007
• Last updated: December 9, 2013
• Start date: September 2007

Study information

• Verified date: December 2013
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 154
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation

2. HIV-1- infected males or females greater than or equal to 18 years of age with documented positive serology Enzyme-linked Immuno Sorbert Assay (ELISA) confirmed by Western blot

3. No prior nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) use of more than 10 days AND

4. No prior use of other classes of antiretrovirals (ARVs) of more than 2 weeks duration

5. Males with CD4+ count less than 400 cells/mm cubed or females with CD4+ count less than 250 cells/mm cubed

6. NVP and ATV/r susceptibility on screening HIV-1 genotypic resistance assay

7. Adequate renal function defined as a calculated creatinine clearance greater than or equal to50 ml/min according to the Cockcroft-Gault formula

8. Karnofsky score greater than or equal to 70 (see Appendix 10.7)

9. Acceptable medical history, as assessed by the investigator

Exclusion criteria:

1. History of active drug or alcohol abuse within 2 years prior to study entry (at the investigators discretion)

2. Hepatic cirrhosis with stage Child-Pugh B or C hepatic impairment

3. Female patients of child-bearing potential who:

have a positive serum pregnancy test at screening, are breast feeding, are planning to become pregnant, are not willing to use a barrier method of contraception, or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives

4. Laboratory parameters greater than Division of Aids (National Institute of Health, USA) (DAIDS) grade 2 (triglycerides greater than DAIDS grade 3, total cholesterol no restrictions, see Appendix 10.1)

5. Active hepatitis B or C disease, defined as HBsAg-positive or Hepatitis C Virus (HCV) RNA positive with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ALT/AST greater than2.5x Upper Limit of Normal (ULN) (greater than DAIDS grade 1)

6. Known hypersensitivity to any ingredients in nevirapine or atazanavir

7. Patients who are receiving concomitant treatments which are not permitted, as listed in Appendix 10.6

8. Use of other investigational medications within 30 days before study entry or during the trial

9. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with prednisone)

10. Patients with Progressive Multifocal Leukoencephalopathy (PML), visceral Kaposi's Sarcoma (KS), and/or any lymphoma

11. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at the screening visit

12. Patients who are receiving systemic chemotherapy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections

Intervention

Drug:
• tenofovir DF 300 mg QD
300 mg QD
• tenofovir DF 300 mg QD
300 mg QD
• emtricitabine 200 mg QD
200 mg QD
• emtricitabine 200 mg QD
200 mg QD
• Nevirapine 200 mg BID
200 mg BID
• Atazanavir 300 mg
300 mg QD
• Ritonavir 100 mg
100 mg QD

Locations

Country	Name	City	State
United States	1100.1512.27 Boehringer Ingelheim Investigational Site	Annandale	Virginia
United States	1100.1512.28 Boehringer Ingelheim Investigational Site	Beverly Hills	California
United States	1100.1512.13 Boehringer Ingelheim Investigational Site	Charleston	South Carolina
United States	1100.1512.30 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	1100.1512.15 Boehringer Ingelheim Investigational Site	Denver	Colorado
United States	1100.1512.17 Boehringer Ingelheim Investigational Site	Fort Lauderdale	Florida
United States	1100.1512.19 Boehringer Ingelheim Investigational Site	Fort Worth	Texas
United States	1100.1512.16 Boehringer Ingelheim Investigational Site	Houston	Texas
United States	1100.1512.24 Boehringer Ingelheim Investigational Site	Houston	Texas
United States	1100.1512.20 Boehringer Ingelheim Investigational Site	Los Angeles	California
United States	1100.1512.29 Boehringer Ingelheim Investigational Site	Maywood	Illinois
United States	1100.1512.11 Boehringer Ingelheim Investigational Site	Neptune	New Jersey
United States	1100.1512.25 Boehringer Ingelheim Investigational Site	Newark	New Jersey
United States	1100.1512.14 Boehringer Ingelheim Investigational Site	Orlando	Florida
United States	1100.1512.21 Boehringer Ingelheim Investigational Site	Philadelphia	Pennsylvania
United States	1100.1512.18 Boehringer Ingelheim Investigational Site	Somers Point	New Jersey
United States	1100.1512.23 Boehringer Ingelheim Investigational Site	Vero Beach	Florida
United States	1100.1512.26 Boehringer Ingelheim Investigational Site	Washington	District of Columbia
United States	1100.1512.22 Boehringer Ingelheim Investigational Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Virologic Response (VR)	VR is defined as HIV viral load of <50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.	baseline to week 48	No
Secondary	Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm	HIV viral load <50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48.	baseline to week 48	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48	HIV viral load <50 copies/ml measured at Week 48 among observed cases on-treatment.	baseline to week 48	No
Secondary	Number of Participants With Virologic Success (FDA Definition)	HIV viral load <50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS).	baseline to week 48	No
Secondary	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants	Time to response whereby patients withdrawing early were censored after their withdrawal	baseline to week 48	No
Secondary	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml		baseline to week 48	No
Secondary	Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response	HIV viral load > 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values < 50 copies/ml)	baseline to week 24 and week 48	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment	Results within time windows, patients on-treatment	baseline to week 2	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment	Results within time windows, patients on-treatment	baseline to week 4	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment	Results within time windows, patients on-treatment	baseline to week 6	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment	Results within time windows, patients on-treatment	baseline to week 8	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment	Results within time windows, patients on-treatment	baseline to week 12	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment	Results within time windows, patients on-treatment	baseline to week 24	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment	Results within time windows, patients on-treatment	baseline to week 36	No
Secondary	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment	Results within time windows, patients on-treatment	baseline to week 48	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment	Results within time windows, patients on-treatment	baseline to week 2	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment	Results within time windows, patients on-treatment	baseline to week 4	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment	Results within time windows, patients on-treatment	baseline to week 6	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment	Results within time windows, patients on-treatment	baseline to week 8	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment	Results within time windows, patients on-treatment	baseline to week 12	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment	Results within time windows, patients on-treatment	baseline to week 24	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment	Results within time windows, patients on-treatment	baseline to week 36	No
Secondary	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment	Results within time windows, patients on-treatment	baseline to week 48	No
Secondary	Number of Patients With Virologic Rebound to >400 Copies/ml	HIV viral load >400 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values < 50 copies/ml)	baseline to week 48	No
Secondary	AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death	AIDS defining illnesses include: Aspergillosis, Bartonellosis, Candidiasis, Cervical cancer, Chagas disease, Coccidiodomycosis, Cryptococcosis, Cytomegalovirus retinus, encephalopathy, Herpes Simplex Virus, Histoplasmosis, Isosporiasis, Kaposi's sarcoma, Leishmaniasis, Microsporidiosis, Mycobacterium avium complex, mycobacterium (non-tuberculous), Nocardiosis, Pneumocystis carinii pneumonia, Pneumonia, Progressive Multifocal Leukoencephalopathy, Rhodococcus equi, Salmonella, Toxoplasmosis, Wasting.; Number of cases (no time-to analysis was performed due to small numbers).	baseline to week 48	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 2.	Patients on-treatment, data within time windows	baseline to week 2	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 4.	Patients on-treatment, data within time windows	baseline to week 4	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 6.	Patients on-treatment, data within time windows	baseline to week 6	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 8.	Patients on-treatment, data within time windows	baseline to week 8	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 12.	Patients on-treatment, data within time windows	baseline to week 12	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 24.	Patients on-treatment, data within time windows	baseline to week 24	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 36.	Patients on-treatment, data within time windows	baseline to week 36	No
Secondary	Change in CD4+ Cell Count From Baseline to Week 48.	Patients on-treatment, data within time windows	baseline to week 48	No
Secondary	Change in Fasting Plasma Total Cholesterol Level		baseline to week 48	No
Secondary	Change in Fasting Plasma Triglycerides Level		baseline to week 48	No
Secondary	Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level		baseline to week 48	No
Secondary	Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level		baseline to week 48	No
Secondary	Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio		baseline to week 48	No
Secondary	Change in Framingham Score	Framingham prediction of 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction [MI] or CHD death) based on the patient's gender, age, systolic blood pressure, total cholesterol, HDL-c and smoking status. The scale for the estimated risk ranges from 0 to 30%.	baseline to week 48	No
Secondary	Change in Revised Framingham Score According to the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group		baseline to week 48	No
Secondary	Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48	using 4-variable Modification of Diet in Renal Disease (MDRD) formula	baseline to week 48	No
Secondary	Percentage Adherence by Pill Count	Number of pills not returned / number of treatment days in percent (%)	baseline to week 48	No
Secondary	Number of Participants With Genotypic Resistance at the Time of Virologic Failure.	Genotypic resistance was measured by the following: Plasma samples for HIV-1 resistance were analyzed using a standard clinical assay that generates a virtual phenotypic interpretation of HIV-1 sequence data and predicts susceptibility or resistance of the isolate to approved ARVs. This analysis has not been performed.	baseline to week 48	No
Secondary	Incidence of Patients With AIDS Progression at Each Visit	Cumulative incidence of patients with AIDS progression are shown	baseline to week 52	No
Secondary	Proportion of Patients Reporting CNS Side Effects of Any Severity		baseline to week 52	No
Secondary	Proportion of Patients Reporting Hepatic Events of Any Severity		baseline to week 52	No
Secondary	Proportion of Patients Reporting Rash of Any Severity		baseline to week 52	No
Secondary	Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities		baseline to week 52	No

External Links

•   Link